On Monday, BioXcel Therapeutics Inc (NASDAQ: BTAI) opened higher 12.27% from the last session, before settling in for the closing price of $1.63. Price fluctuations for BTAI have ranged from $1.17 to $9.78 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 6.20% over the past five years. Company’s average yearly earnings per share was noted 72.31% at the time writing. With a float of $21.03 million, this company’s outstanding shares have now reached $21.87 million.
BioXcel Therapeutics Inc (BTAI) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of BioXcel Therapeutics Inc is 3.85%, while institutional ownership is 10.76%. The most recent insider transaction that took place on Dec 16 ’24, was worth 58. In this transaction an insider of this company sold 165 shares at a rate of $0.35, taking the stock ownership to the 19,957 shares. Before that another transaction happened on Dec 16 ’24, when Company’s CEO and President sold 3,117 for $0.36, making the entire transaction worth $1,131. This insider now owns 59,605 shares in total.
BioXcel Therapeutics Inc (BTAI) Latest Financial update
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -3.56 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -5.14) by 1.58. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.72 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 55.37% during the next five years compared to 6.20% growth over the previous five years of trading.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Trading Performance Indicators
Check out the current performance indicators for BioXcel Therapeutics Inc (BTAI). In the past quarter, the stock posted a quick ratio of 1.16. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 53.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -9.70, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -3.04 in one year’s time.
Technical Analysis of BioXcel Therapeutics Inc (BTAI)
BioXcel Therapeutics Inc (NASDAQ: BTAI) saw its 5-day average volume 0.82 million, a negative change from its year-to-date volume of 4.31 million. As of the previous 9 days, the stock’s Stochastic %D was 27.96%.
During the past 100 days, BioXcel Therapeutics Inc’s (BTAI) raw stochastic average was set at 7.82%, which indicates a significant decrease from 46.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.1600 in the past 14 days, which was lower than the 0.3990 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.4500, while its 200-day Moving Average is $2.4169. Nevertheless, the first resistance level for the watch stands at $1.9164 in the near term. At $2.0029, the stock is likely to face the second major resistance level. The third major resistance level sits at $2.1457. If the price goes on to break the first support level at $1.6871, it is likely to go to the next support level at $1.5443. The third support level lies at $1.4578 if the price breaches the second support level.
BioXcel Therapeutics Inc (NASDAQ: BTAI) Key Stats
There are currently 16,009K shares outstanding in the company with a market cap of 40.02 million. Presently, the company’s annual sales total 2,270 K according to its annual income of -59,600 K. Last quarter, the company’s sales amounted to 120 K and its income totaled -19,190 K.
